PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 115 filers reported holding PUMA BIOTECHNOLOGY INC in Q4 2013. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,384,000 | -61.0% | 14,000 | -52.8% | 0.00% | -75.0% |
| Q3 2017 | $3,549,000 | +370.7% | 29,632 | +46.3% | 0.01% | +300.0% |
| Q1 2017 | $754,000 | +40.1% | 20,248 | +15.6% | 0.00% | +100.0% |
| Q4 2016 | $538,000 | -55.6% | 17,508 | -3.3% | 0.00% | -66.7% |
| Q3 2016 | $1,213,000 | -88.7% | 18,104 | -60.1% | 0.00% | -85.7% |
| Q1 2015 | $10,704,000 | -20.4% | 45,333 | -36.2% | 0.02% | -25.0% |
| Q4 2014 | $13,453,000 | -20.7% | 71,075 | -0.1% | 0.03% | -22.2% |
| Q3 2014 | $16,967,000 | +288.3% | 71,118 | +7.4% | 0.04% | +300.0% |
| Q2 2014 | $4,369,000 | -33.9% | 66,188 | +4.3% | 0.01% | -40.0% |
| Q1 2014 | $6,612,000 | -27.4% | 63,488 | -27.9% | 0.02% | -31.8% |
| Q4 2013 | $9,113,000 | +85.8% | 88,026 | -3.7% | 0.02% | +69.2% |
| Q3 2013 | $4,904,000 | +20.9% | 91,388 | 0.0% | 0.01% | +8.3% |
| Q2 2013 | $4,055,000 | – | 91,388 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Athyrium Capital Management, LP | 1,792,114 | $5,108,000 | 2.15% |
| Camber Capital Management LP | 4,235,000 | $12,070,000 | 0.52% |
| Kynam Capital Management, LP | 579,915 | $1,653,000 | 0.42% |
| GLOBEFLEX CAPITAL L P | 419,322 | $1,195,000 | 0.29% |
| Eversept Partners, LP | 1,435,077 | $4,089,969 | 0.29% |
| ARMISTICE CAPITAL, LLC | 1,500,000 | $4,275,000 | 0.08% |
| RICE HALL JAMES & ASSOCIATES, LLC | 506,066 | $1,442,000 | 0.07% |
| XTX Topco Ltd | 36,130 | $103,000 | 0.04% |
| State of Wyoming | 20,732 | $59,000 | 0.04% |
| Patriot Financial Group Insurance Agency, LLC | 55,500 | $158,000 | 0.03% |